Trial Profile

A Phase I/II clinical study with HORA-001(HORA CRB1) to Treat Inherited Retinal Dystrophies

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HORA-001 (Primary)
Indications Retinal dystrophies
Focus Therapeutic Use
Sponsors Coave Therapeutics

Most Recent Events

26 Mar 2020 New trial record
18 Mar 2020 According to an Horama media release, the company expects to initiate a Phase I/II clinical study with HORA-001 in 2023, based on current timelines, and subject to regulatory review.
18 Mar 2020 According to an Horama media release, the company announced an exclusive licensing agreement with the Leiden University Medical Center (LUMC) for global rights to a gene therapy program to treat the Inherited Retinal Dystrophy associated with pathogenic CRB1 gene mutations.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com